[Treatment of congenital toxoplasmosis].
D000906:Antibodies / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005492:Folic Acid / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007933:Leucomycins / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011739:Pyrimethamine / Q000627:therapeutic use; D013411:Sulfadiazine / Q000627:therapeutic use; D014122:Toxoplasma / Q000276:immunology; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy* / Q000276:immunology
D000906:Antibodies; D007933:Leucomycins; D013411:Sulfadiazine; D005492:Folic Acid; D011241:Prednisone; D008775:Methylprednisolone; D011739:Pyrimethamine
Die Behandlung der konnatalen Toxoplasmose.